Optic neuritis is associated with multiple sclerosis (MS) and is characterized by inflammatory damage to the optic nerve that sends visual signals to the brain. About 20% of people with MS experience optic neuritis as the first symptom, but not all of those with optic neuritis develop MS. Many neurologists consider optic neuritis as an early sign or first warning of the disease. Patients may experience blurred vision, complete loss of sight, a blurry or blind spot in the center of their vision, or color changes. They may also experience pain or flashes of light when moving their eyes.
An antibody analysis has identified two biomarkers that can be used to predict the development of multiple sclerosis (MS) in people with optic neuritis, a study reports. …
Read moreResearchers have tested a new compound called ST266 in a mouse model of multiple sclerosis (MS) and found that its anti-inflammatory properties prevent the loss of cells related to optic neuritis — a condition that leads to vision loss. The study,…
A treatment delivered as a nasal solution helped to preserve eye neurons and improve eyesight in a mouse model of multiple sclerosis (MS), a recent study demonstrated — suggesting that it may be possible to deliver drugs that target the brain…
Genetically silencing the transcription factor Nrf2 in a mouse model of multiple sclerosis (MS) results in visual deficits, inflammation of the optic nerve, and degeneration of the retinal ganglion cells (RGC), according to a study published in the scientific journal Molecular Vision.
Optic neuritis is one of the symptoms of which those of us who live with multiple sclerosis on a daily basis know can set us apart from others. We are fully, and often painfully, aware that everyone is different.
A Phase 2 clinical trial testing the efficacy of a common antihistamine, clemastine fumarate, to treat optic nerve damage in people with multiple sclerosis (MS) found the drug able to slightly reverse damage to their visual system. The study, conducted by researchers…
Researchers from the University College London (UCL) found that the anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis — often the first symptom of multiple sclerosis (MS) — a condition that causes the nerves carrying information between the eyes…
Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a…
The American Academy of Neurology (AAN) recently announced the results of a new study that evaluated an experimental drug for multiple sclerosis (MS) with the potential to repair damaged myelin layers, a fatty material that covers and protects neurons.
Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.
Get regular updates to your inbox.